Apellis Pharmaceuticals Inc’s recently made public that its Chief Financial Officer Sullivan Timothy Eugene unloaded Company’s shares for reported $0.23 million on Apr 01 ’24. In the deal valued at $58.66 per share,4,000 shares were sold. As a result of this transaction, Sullivan Timothy Eugene now holds 93,338 shares worth roughly $5.02 million.
Then, Dunlop A. Sinclair sold 18,681 shares, generating $1,068,161 in total proceeds. Upon selling the shares at $57.18, the Director now owns 173,998 shares.
Before that, DeLong Mark Jeffrey sold 9,913 shares. Apellis Pharmaceuticals Inc shares valued at $564,050 were divested by the Chief Business & Strat Officer at a price of $56.90 per share. As a result of the transaction, DeLong Mark Jeffrey now holds 54,693 shares, worth roughly $2.94 million.
Jefferies upgraded its Apellis Pharmaceuticals Inc [APLS] rating to a Buy from a a Hold in a research note published on February 05, 2024; the price target was increased to $80 from $68. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who decreased its forecast for the stock in mid December from “an Overweight” to “an Equal weight”. Goldman began covering APLS with “Buy” recommendation on November 09, 2023. Mizuho started covering the stock on November 02, 2023. It rated APLS as “a Neutral”.
Price Performance Review of APLS
On Monday, Apellis Pharmaceuticals Inc [NASDAQ:APLS] saw its stock fall -3.76% to $53.81. Over the last five days, the stock has lost -9.88%. Apellis Pharmaceuticals Inc shares have fallen nearly -10.11% since the year began. Nevertheless, the stocks have fallen -30.41% over the past one year. While a 52-week high of $94.75 was reached on 01/09/24, a 52-week low of $19.83 was recorded on 03/20/24. SMA at 50 days reached $62.28, while 200 days put it at $54.03. A total of 0.81 million shares were traded, compared to the trading of 1.08 million shares in the previous session.
Levels Of Support And Resistance For APLS Stock
The 24-hour chart illustrates a support level at 53.05, which if violated will result in even more drops to 52.29. On the upside, there is a resistance level at 55.28. A further resistance level may holdings at 56.75. The Relative Strength Index (RSI) on the 14-day chart is 36.36, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.48, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 90.77%. Stochastics %K at 30.75% indicates the stock is a holding.
How much short interest is there in Apellis Pharmaceuticals Inc?
A steep rise in short interest was recorded in Apellis Pharmaceuticals Inc stocks on Mar 15, 2024, growing by 0.32 million shares to a total of 10.59 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 10.27 million shares. There was a rise of 3.02%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 10.19% of the overall stock float, the days-to-cover ratio (short ratio) rose to 7.54.
